The global sector for CAR T-cell therapy in treating Non-Hodgkin's lymphoma is witnessing significant growth. This phenomenon is fueled by several factors, including growing prevalence of Non-Hodgkin's lymphoma, progresses in CAR T-cell therapy technology, and increasing adoption by healthcare providers. The market is categorized based on factors s